



Penile Erection Induced by Scoparone from *Artemisia capillaris* through the Nitric Oxide-Cyclic Guanosine Monophosphate Signaling Pathway

Bo Ram Choi^{1,*}, Hye Kyung Kim^{2,*}, Jong Kwan Park¹

¹Department of Urology, Research Institute of Clinical Medicine, Biomedical Research Institute, and Clinical Trial Center of Medical Device, Chonbuk National University Medical School, Jeonju, ²College of Pharmacy, Kyungshung University, Busan, Korea

Purpose: The objective of this study was to evaluate the relaxant effect of scoparone from *Artemisia capillaris* on rabbit penile corpus cavernosum smooth muscle (PCCSM) and to elucidate the mechanism of action of scoparone for the treatment of erectile dysfunction (ED).

Materials and Methods: PCCSM that had been precontracted with phenylephrine was treated with 3 *Artemisia* herbs (*A. princeps*, *A. capillaris*, and *A. iwayomogi*) and 3 fractions (*n*-hexane, ethyl acetate, and *n*-butanol) with different concentrations (0.1, 0.5, 1.0, and 2.0 mg/mL). Four components (esculetin, scopoletin, capillarisin, and scoparone) isolated from *A. capillaris* were also evaluated. The PCCSM was preincubated with *N* ω -nitro-L-arginine methyl ester hydrochloride (L-NAME) and 1H-[1,2,4]oxadiazolo [4,3-*a*]quinoxalin-1-one (ODQ). Cyclic nucleotides in the perfusate were measured by a radioimmunoassay. The interactions of scoparone with udenafil and rolipram were also evaluated.

Results: *A. capillaris* extract relaxed PCCSM in a concentration-dependent manner. Scoparone had the highest relaxant effect on PCCSM among the 4 components (esculetin, scopoletin, capillarisin, and scoparone) isolated from the ethyl acetate fraction. The application of scoparone on PCCSM pretreated with L-NAME and ODQ led to significantly less relaxation. Scoparone also increased the cyclic guanosine monophosphate (cGMP) levels in the perfusate in a concentration-dependent manner. Furthermore, scoparone enhanced udenafil- and rolipram-induced relaxation of the PCCSM.

Conclusions: Scoparone relaxed the PCCSM mainly by activating the nitric oxide-cGMP signaling pathway, and it may be a new promising treatment for ED patients who do not completely respond to udenafil.

Key Words: Coumarins; Erectile dysfunction; Nitric oxide; Phosphodiesterase 5 inhibitors

Received: Jul 4, 2017; Revised: Aug 25, 2017; Accepted: Sep 14, 2017; Published online Nov 21, 2017

Correspondence to: Jong Kwan Park  <https://orcid.org/0000-0001-9682-2081>

Department of Urology, Chonbuk National University Medical School, 20 Geonji-ro, Deokjin-gu, Jeonju 54907, Korea.
Tel: +82-63-250-1510, Fax: +82-63-250-1564, E-mail: rain@chonbuk.ac.kr

*These authors contributed equally to this work as co-first authors.

Copyright © 2017 Korean Society for Sexual Medicine and Andrology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Erectile dysfunction (ED) is defined as a recurrent inability to achieve and/or maintain an erection sufficient to permit satisfactory sexual activity [1]. ED is a significant global health problem in aging men, affecting approximately 150 million men worldwide [2]. The causes of ED have been classified as psychogenic, organic (neurogenic, hormonal, arterial, venous, and cavernosal), and mixed psychogenic and organic [3]. A number of common risk factors are associated with ED, including age, heart disease, diabetes, hypertension, metabolic syndrome, and physical inactivity [4]. Normal penile erection is dependent upon nitric oxide (NO). NO is supplemented by release from the vascular endothelium, and leads to relaxation of the smooth muscle in the penile arteries [5]. NO activates soluble guanylate cyclase to increase the levels of the cellular second messenger cyclic guanosine monophosphate (cGMP) in smooth muscle cells [6]. The activation of cGMP-specific protein kinases induces the opening of potassium channels, which act together with calcium channels to decrease the intracellular level of calcium ions and to lead to smooth muscle relaxation in the cavernosum [7].

Artemisia plants, particularly *A. princeps*, *A. capillaris*, and *A. iwayomogi*, are important medicinal materials in traditional Asian medicine [8]. *A. capillaris* Thunb has been widely used as a traditional herbal medicine for liver cirrhosis, liver cancer, jaundice, and cholecystitis in Asian countries [9]. Several compounds have been isolated from *A. capillaris*, including capillarisin and coumarin derivatives, such as esculetin, scopoletin, and scoparone [10]. 6,7-dimethoxy coumarin (scoparone) is an active constituent isolated from the shoot of *A. capillaris* that has been used as an anti-inflammatory and choleric agent for the treatment of hepatitis [11,12]. In addition, it was found that scoparone exerted vasodilatory activity in a heart perfusion model in rats [13].

The objective of the present study was to evaluate the effect of scoparone on penile corpus cavernosum smooth muscle (PCCSM) and to elucidate the possible mechanism of the action of scoparone on ED.

MATERIALS AND METHODS

1. Chemicals and reagents

N- ω -nitro-L-arginine methyl ester hydrochloride (L-NAME), 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), L-phenylephrine (Phe), dimethyl sulfoxide, rolipram, scopoletin, and scoparone (Fig. 1) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Esculetin and capillarisin were purchased from Wako Pure Chemical Industries (Osaka, Japan). Udenafil was donated by Dong-A ST Company (Seoul, Korea). All other chemicals were purchased from standard suppliers.

2. Activity-guided isolation

Shade-dried samples of *A. princeps*, *A. capillaris*, and *A. iwayomogi* (2.5 kg) were pulverized and extracted 3 times with ethanol for 3 hours using an ultrasonic bath (model 8510 DHT; Branson, Danbury, CT, USA). The ethanol extract (98.55 g) from *A. capillaris* was partitioned with *n*-hexane, ethyl acetate, and *n*-butanol in succession. The active ethyl acetate fraction (35.03 g) was chromatographed on silica gel using a gradient dichloromethane-ethyl acetate system to yield 24 fractions. Among these fractions, fraction 13 (1.08 g) showed relaxant effects and scoparone was identified as the active component by further purification on a Sephadex LH-20 with methanol elution. The chemical structure of scoparone was determined by ^1H and ^{13}C nuclear magnetic resonance and electrospray ionization mass spectroscopy data (Fig. 1).

3. Ethics statement

All animal procedures for this study were performed in accordance with the regulations for the care and use of laboratory animals that were approved by the Institutional Animal Care and Use Committee of the Laboratory Animal Center (IACUC, cuh-IACUC-2016-12), and all efforts were made to minimize animal suffering.

4. Tissue preparation

The rabbits were intravenously anesthetized with 50 mg/kg of ketamine plus 25 mg/kg of rumpun (xylazine hydrochloride) (Bayer, Ansan, Korea) and exsanguinated. The penis was excised rapidly.

An *ex vivo* penile perfusion model was constructed,




Fig. 1. Total ion chromatograms of the ethyl acetate extract of *Artemisia capillaris* and purified scoparone. Crude ethyl acetate extract of *A. capillaris* extract (A), purified scoparone (B), ultraviolet spectrum of scoparone at 34.09 minutes from the crude extract photodiode array chromatogram (C), and a mass spectrogram of scoparone at 34.09 minutes from the crude extract total ion chromatogram (D).

with the penis prepared as described previously [14]. The entire penis, including the urethra, was rapidly excised from the pubic bone. The urethra was dissected free from the penile body. The glans penis was cut out until the corpus cavernosum was exposed to air through a small opening measuring 5 mm in diameter. Two small polyethylene tubes (inner diameter, 1.2 mm; outer diameter, 1.7 mm; Natsume, Tokyo, Japan) were inserted into the proximal opening of the crurae for inflow and ligated with a purse string silk suture to prevent leakage. The penis was immediately perfused interstitially through the cannula with a 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer using a peristaltic pump (0.5 mL/min). After mounting, the tissue was equilibrated for 100 minutes with several adjustments of length until a baseline force was stabilized at 10 g. The chamber for penile perfusion had a hole

at the bottom to allow collection of the perfusate. The penis was perfused with scoparone for 2 hours to measure cGMP concentration in the perfusate.

5. Measurement of tension in the penile corpus cavernosum smooth muscle

The PCCSM was then carefully dissected free from the surrounding tunica albuginea. A strip of PCCSM (1.5 × 1.5 × 7.0 mm) was prepared from a healthy male New Zealand white rabbit weighing 2.5 to 3.0 kg and was vertically placed in a 2 mL organ chamber with one end connected with a thread to the prong of a force transducer (FT03; Grass Telefactor, West Warwick, RI, USA) and the other end secured with a thread to a holder for isometric tension measurement. After stabilization, 10^{-5} M of Phe was added to adjust the maximal contractile tension, and

then the samples were added to the organ chamber with the desired final concentration. Experiments were performed via cumulative dose-dependent relaxation responses to *A. princeps*, *A. capillaris*, and *A. iwayomogi* extracts (0.1, 0.5, 1.0, or 2.0 mg/mL) in the PCCSM that had been precontracted with 10^{-5} M of Phe. The relaxant effects of the fractions (*n*-hexane, ethyl acetate, and *n*-butanol) from *A. capillaris* were studied by cumulative addition at concentrations of 0.1 to 2.0 mg/mL at the plateau of the Phe-induced contraction. Scoparone (10^{-7} , 10^{-6} , 10^{-5} , and 10^{-4} M) was added to the perfusion medium in sequence, each for 10 minutes. The PCCSM was preincubated with L-NAME (10^{-3} M) for 30 minutes to block NO synthase or preincubated with ODQ (10^{-5} M) for 30 minutes to block guanylate cyclase.

6. Radioimmunoassay of cyclic guanosine monophosphate concentrations

Levels of cGMP were measured with a specific radioimmunoassay, as described previously [15]. Briefly, standards or samples were taken up in a final volume of 100 μ L of 50 mM sodium acetate buffer (pH 4.8) containing theophylline (8 mM), and then 100 μ L of diluted cGMP antiserum (Calbiochem-Novabiochem, San Diego, CA, USA) and iodinated 2'-O-monosuccinyl-guanosine 3',5'-cyclic monophosphate tyrosyl methyl ester (125 I-ScGMP-TME, 10,000 counts/min/100 μ L) were added for the measurement of cGMP. For the acetylation reaction, 5 μ L of a mixture of acetic anhydride and triethylamine (1:2 dilution) was added to the assay tube before antiserum and tracer were also added. The bound form was separated from the free form by charcoal suspension. The amount of cGMP was expressed as femtomoles per milligram of PCCSM.

7. Interaction of scoparone with the effects of udenafil or rolipram on penile corpus cavernosum smooth muscle tension

The strip of PCCSM was preincubated with udenafil (10^{-7} M) or rolipram (10^{-6} M) for 30 minutes, and scoparone (10^{-6} M) was added to the organ chamber after Phe-induced contraction. Inversely, udenafil or rolipram was also added to the organ chamber of PCCSM preincubated with scoparone for 30 minutes after Phe-induced contraction.

8. Statistical evaluation

The submaximal penile contractile responses induced by Phe were considered to be the values corresponding to 100%, and all subsequent responses to scoparone were expressed as a percentage of this value. The results were expressed as the mean \pm standard deviation, with *n* representing the number of tissues in each group. The statistical significance of the differences was calculated by 1-way analysis of variance, followed by the Bonferroni multiple comparison test. Concentration-dependent responses before and after the treatment with blockers were compared by the paired Student t-test. The p-values < 0.05 were considered to indicate statistical significance.

RESULTS

1. Evaluation of the cumulative dose of the ethanol extract of *Artemisia* herbs

Artemisia herbs demonstrated a significant and concentration-dependent relaxant effect (Fig. 2). The amount of relaxation induced by 0.1, 0.5, 1.0, and 2.0 mg/mL of *A. capillaris* extract was $21.95\% \pm 1.71\%$, $41.19\% \pm 1.10\%$,




Fig. 2. Percentage of relaxation induced by the ethanol extract of *Artemisia* herbs (*n* = 4). The penile corpus cavernosum smooth muscle that had been precontracted with 10^{-5} M of phenylephrine (Phe) was treated with 4 concentrations of *Artemisia* herbs. The submaximal penile contractile responses induced by the Phe solution were taken as 100%, and all subsequent responses to *Artemisia* herbs were expressed as a percentage of this value. Each point represents the mean \pm standard deviation of the percentages (**p* < 0.05 vs. 0.1 mg/mL, ***p* < 0.01 vs. 0.1 mg/mL).

60.28% ± 1.44%, and 68.27% ± 1.24%, respectively. *A. capillaris* had the most potent relaxant effect among the 3 *Artemisia* herbs.

2. Effect of *Artemisia capillaris* fractions on penile corpus cavernosum smooth muscle

The Phe-precontracted PCCSM was treated with *n*-hexane, ethyl acetate, and *n*-butanol fractions. The relaxant effect of the ethyl acetate fraction was found to be the most potent among the 3 fractions. Compared with that of *n*-hexane and *n*-butanol fractions, the ethyl acetate fraction attained a maximum value of 122.92% ± 1.95%, as shown in Fig. 3. This value was obtained for the 0.1 mg/mL of ethyl acetate fraction, which relaxed the PCCSM in a concentration-dependent manner.

3. Percentage of relaxation induced by esculetin, scopoletin, capillarisin, and scoparone

Experiments were performed to investigate the cumulative dose-dependent relaxant responses to esculetin, scopoletin, capillarisin, and scoparone in the Phe-precontracted PCCSM. Fig. 4 shows that esculetin, scopoletin, capillarisin, and scoparone exerted a significant and con-




Fig. 3. Percentage of relaxation induced by the fractions partitioned with *n*-hexane, ethyl acetate, and *n*-butanol (n=4). The penile corpus cavernosum smooth muscle that had been precontracted with 10⁻⁵ M of phenylephrine (Phe) was treated with 4 concentrations of each fraction. The submaximal penile contractile responses induced by Phe were taken as 100%, and all subsequent responses to *Artemisia capillaris* fractions were expressed as a percentage of this value. Each point represents the mean ± standard deviation of the percentages (*p < 0.01 vs. 0.1 mg/mL).

centration-dependent relaxant effect. Scoparone had the most potent relaxant effect of the 4 compounds. The amount of relaxation induced by 10⁻⁴ M of esculetin, scopoletin, capillarisin, and scoparone was 6.82% ± 3.31%, 21.68% ± 5.62%, 77.95% ± 4.67%, and 102.82% ± 3.97%, respectively.

4. Cumulative effect of scoparone on penile corpus cavernosum smooth muscle with/without Nω-nitro-L-arginine methyl ester hydrochloride preincubation

The amount of relaxation induced by 10⁻⁷, 10⁻⁶, 10⁻⁵, and 10⁻⁴ M of scoparone was 6.30% ± 2.50%, 12.54% ± 1.34%, 30.63% ± 1.58%, and 89.63% ± 1.87%, respectively (Fig. 5A). Scoparone exerted a significant and concentration-dependent relaxant effect. The application of scoparone on PCCSM preincubated with L-NAME significantly decreased the relaxation. The amount of relaxation induced by scoparone in L-NAME-preincubated PCCSM was 5.40% ± 1.12%, 8.75% ± 0.83%, 19.40% ± 0.94%, and 54.26% ± 2.75%, respectively.




Fig. 4. Percentage of relaxation induced by esculetin, scopoletin, capillarisin, and scoparone (n=4). The penile corpus cavernosum smooth muscle that had been precontracted with 10⁻⁵ M of phenylephrine (Phe) was treated at 4 concentrations of esculetin, scopoletin, capillarisin, and scoparone. The submaximal penile contractile responses induced by Phe were taken as 100%, and all subsequent responses to esculetin, scopoletin, capillarisin, and scoparone were expressed as a percentage of this value. Each point represents the mean ± standard deviation of the percentages. Statistical analysis was carried out by analysis of variance followed by the Bonferroni test (*p < 0.05 vs. 10⁻⁷ M, **p < 0.01 vs. 10⁻⁷ M).




Fig. 5. Relaxant effect of scoparone in L-phenylephrine (Phe)-induced contraction (n=4). Penile corpus cavernosum smooth muscle contracted by Phe (10^{-5} M) that was preincubated with N ω -nitro-L-arginine methyl ester hydrochloride (L-NAME, 10^{-3} M) (A) or 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10^{-5} M) (B) was treated with 4 concentrations of scoparone (10^{-7} , 10^{-6} , 10^{-5} , and 10^{-4} M). The submaximal penile contractile responses induced by Phe were taken as the 100% values, and all subsequent responses to scoparone were expressed as a percentage of this value. Each point represents the mean \pm standard deviation of the percentages. Statistical analysis was carried out by analysis of variance followed by the Bonferroni test (* $p < 0.05$ vs. scoparone, ** $p < 0.01$ vs. scoparone).

5. Cumulative effect of scoparone on penile corpus cavernosum smooth muscle with/without 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one preincubation

As shown in Fig. 5B, scoparone relaxed the PCCSM in a dose-dependent manner, with a maximum value of $85.02\% \pm 2.74\%$ at a concentration of 10^{-4} M. The relaxation induced by scoparone on ODQ-preincubated PCCSM was significantly inhibited. Preincubation with ODQ reduced the amount of relaxation to $4.99\% \pm 0.77\%$, $8.73\% \pm 1.76\%$, $13.06\% \pm 0.87\%$, and $51.13\% \pm 2.07\%$, respectively.

6. Effect of scoparone on cyclic guanosine monophosphate in the perfusate

cGMP levels significantly increased in PCCSM perfused by scoparone in a concentration-dependent manner (Fig. 6). The highest level of cGMP was obtained at 10^{-4} M. cGMP levels increased by 223.10 ± 15.40 , 285.70 ± 6.00 , 386.80 ± 14.70 , and 450.90 ± 29.70 fmol/mg in response to 10^{-7} , 10^{-6} , 10^{-5} and 10^{-4} M of scoparone, respectively.




Fig. 6. Effects of scoparone (10^{-7} , 10^{-6} , 10^{-5} , and 10^{-4} M) on cyclic guanosine monophosphate (cGMP) levels in the perfusate. Each point represents the mean \pm standard deviation of the percentages. Statistical analysis was carried out by analysis of variance followed by the Bonferroni test (** $p < 0.01$ vs. control).

7. Effect of scoparone on penile corpus cavernosum smooth muscle preincubated with udenafil or rolipram

The relaxation induced by a single dose of udenafil (10^{-7} M) in Phe-precontracted PCCSM was $10.57\% \pm 1.58\%$, and the application of scoparone (10^{-6} M) alone induced a relaxation of $14.36\% \pm 1.53\%$ in Phe-precontracted PCCSM (Fig. 7A). The combined relaxation induced by




Fig. 7. Interaction of scoparone (SCOP, 10^{-6} M) with udenafil (UDE, 10^{-7} M) or rolipram (ROL 10^{-6} M) ($n=4$). Effects of different concentrations of UDE (A) and ROL (B) in penile corpus cavernosum smooth muscle (PCCSM) contracted by phenylephrine (Phe, 10^{-5} M). Each point represents the mean \pm standard deviation of the percentages of maximal relaxation of the preceding submaximal contractile responses. Statistical analysis was carried out by analysis of variance followed by the Bonferroni test (** $p < 0.01$ vs. UDE or ROL). (A) UDE+SCOP refers to scoparone-induced relaxation in the udenafil-preincubated PCCSM. (A) SCOP+UDE indicates udenafil-induced relaxation in the scoparone-preincubated PCCSM. (B) ROL+SCOP refers to scoparone-induced relaxation in the rolipram-preincubated PCCSM. (B) SCOP+ROL indicates rolipram-induced relaxation in the scoparone-preincubated PCCSM.

udenafil and scoparone was $24.14\% \pm 1.66\%$ in udenafil-preincubated PCCSM and $25.77\% \pm 0.85\%$ in scoparone-preincubated PCCSM, respectively. Scoparone markedly enhanced udenafil-induced relaxation more than 2-fold ($p < 0.01$). The relaxation induced by a single dose of rolipram (10^{-6} M) in Phe-precontracted PCCSM was $9.76\% \pm 3.93\%$, and the application of scoparone (10^{-6} M) alone induced a relaxation of $14.20\% \pm 2.47\%$ in Phe-precontracted PCCSM (Fig. 7B). The combined relaxation induced by rolipram and scoparone was $21.03\% \pm 3.63\%$ in rolipram-preincubated PCCSM and $24.60\% \pm 2.23\%$ in the scoparone-preincubated PCCSM, respectively. Scoparone significantly enhanced the rolipram-induced relaxation more than 2-fold ($p < 0.01$).

DISCUSSION

This study showed that compounds such as esculetin, scopoletin, capillarisin, and scoparone from *A. capillaris* had a significant relaxant effect on rabbit PCCSM in a concentration-dependent manner over the consecutive range of 10^{-7} , 10^{-6} , 10^{-5} , and 10^{-4} M. Scoparone had the most potent relaxant effect of the 4 compounds. As shown in Fig. 3 ~ 5, scoparone significantly relaxed the PCCSM and increased the cGMP levels in the perfusate. These results suggest that the relaxation induced by scoparone may be

mediated by the NO-cGMP pathway. Chuang et al [16] demonstrated that NO activated cytosolic guanylate cyclase to increase intracellular second messenger cGMP levels in smooth muscle cells, leading to the relaxation of smooth muscle cells.

We hypothesized that scoparone-induced relaxation would be attenuated after treatment with ODQ and L-NAME, if activation of the NO-cGMP pathway was involved in the signal pathway. The present study showed that ODQ and L-NAME significantly inhibited scoparone-induced relaxation. Those results suggest that scoparone may contribute to penile erection by activating the NO-cGMP signaling pathway.

Artemisia herbs are widely used as botanical and pharmaceutical medicines because they contain medicinally active compounds [17]. Our results showed that *A. capillaris* had the most potent relaxant effect among the 3 *Artemisia* herbs. *A. capillaris* has antioxidant effects and antimicrobial effects, inhibits the expression of inflammatory proteins in rat liver, and has anticancer activity [18-20]. Previous studies have also demonstrated that several compounds have been successfully isolated from *A. capillaris*, including coumarins (scoparone, esculetin, and scopoletin) and a chromone (capillarisin), and that the concentrations of these compounds are related to the season of harvest [21]. Capillarisin, the most important chro-

mone in *A. capillaris*, was reported to be an effective choleretic substance and to possess a potent inhibitory effect on xanthine oxidase [22]. Scoparone, a major coumarin in *A. capillaris*, caused peripheral vasodilation and showed antioxidant properties by reducing the malondialdehyde and alanine aminotransferase levels in various test animals, as well as anti-hypertensive abilities [23]. Herein, we investigated the possible *ex vivo* effects of *A. capillaris* extracts on rabbit PCCSM. The ethyl acetate fraction of *A. capillaris* extract significantly relaxed PCCSM in comparison to the *n*-hexane fraction and the *n*-butanol fraction. The main effective ingredients of *A. capillaris*, including coumarins (scoparone, esculetin and scopoletin) and a chromone (capillarisin), which induce vascular relaxation [24], were isolated in the ethyl acetate fraction. Scoparone had the most potent relaxant effect among scoparone, esculetin, scopoletin, and capillarisin.

Oral phosphodiesterase type 5 inhibitors (PDE5Is), such as sildenafil, have been commonly used for the treatment of ED patients and have proven to be a valuable therapy in the management of ED, but these medications do have some limitations [25,26]. Most convincingly, Salonia et al [27] reported that PDE5Is were able to improve the erections of approximately 30% to 50% of the patients they studied. Our results showed that scoparone (10^{-6} M) efficiently enhanced sildenafil (10^{-7} M)-induced relaxation more than 2-fold. Scoparone enhanced sildenafil-induced relaxation as a complementary form of medicine and may improve ED in patients who do not completely respond to sildenafil. Men who suffer sexual dysfunction and women who have a husband with ED are searching for alternative medicines to improve erectile function and homeostatic balance [28]. Phosphodiesterase type 4 is characterized by its specific sensitivity to rolipram, which preferentially inhibits cyclic adenosine monophosphate (cAMP) phosphodiesterase in vascular tissues [29]. Intracellular cAMP is generated by adenylyl cyclase and is degraded by cyclic nucleotide phosphodiesterase, the enzyme that catalyzes the hydrolysis of cAMP to 5'-AMP [30]. In this study, we showed that scoparone efficiently enhanced rolipram-induced relaxation more than 2-fold. This finding suggests that scoparone might be useful as an additional agent to improve the erections induced by PDE5Is.

CONCLUSIONS

In conclusion, scoparone exerted a significant relaxant effect on Phe-precontracted PCCSM and increased sildenafil-induced relaxation. The increased cGMP levels in the perfusate and the inhibition of scoparone relaxation with L-NAME and ODQ suggest that mechanism of action of scoparone involves the NO-cGMP pathway. This research supports the possibility that scoparone may be a good candidate as a medication or supplement for ED patients who do not completely respond to sildenafil. Scoparone also might be used as an additional herbal medicine to improve erectile function when a PDE5I induces an incomplete erection.

ACKNOWLEDGEMENTS

This research was supported by Kyungsoong University Research Grants in 2016.

Disclosure

The authors have no potential conflicts of interest to disclose.

Author Contribution

Designed the experiments: Choi BR, Kim HK. Performed the experiments: Kim HK. Analyzed the data: all authors. Wrote the manuscript: all authors. Directed the research project: Park JK. Approved the final manuscript: all authors.

ORCID

Bo Ram Choi, <https://orcid.org/0000-0002-0203-7080>

Hye Kyung Kim, <https://orcid.org/0000-0001-5982-5005>

Jong Kwan Park, <https://orcid.org/0000-0001-9682-2081>

REFERENCES

1. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. *Eur Urol* 2010;57:804-14.
2. Yaman O, Gulpinar O, Hasan T, Ozdol C, Ertas FS, Ozgenci E. Erectile dysfunction may predict coronary artery disease: relationship between coronary artery calcium scoring and erectile dysfunction severity. *Int Urol Nephrol* 2008;40:117-23.
3. Moon HW, Park JW, Lee KW, Jeong HC, Choi JB, Choi SW,

- et al. Administration of Goji (*Lycium Chinense* Mill.) extracts improves erectile function in old aged rat model. *World J Mens Health* 2017;35:43-50.
4. Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. *Arch Intern Med* 2011; 171:1797-803.
 5. Eardley I. Pathophysiology of erectile dysfunction. *Br J Diabetes Vasc Dis* 2002;2:272-6.
 6. Hosogai N, Takakura S, Manda T, Mutoh S. Enzyme activities of the nitric oxide-cGMP pathway in corpus cavernosum isolated from middle-aged rats. *Eur J Pharmacol* 2003; 473:65-70.
 7. Sun K, Zhao C, Chen XF, Kim HK, Choi BR, Huang YR, et al. Ex vivo relaxation effect of *Cuscuta chinensis* extract on rabbit corpus cavernosum. *Asian J Androl* 2013;15:134-7.
 8. Lee MY, Doh EJ, Park CH, Kim YH, Kim ES, Ko BS, et al. Development of SCAR marker for discrimination of *Artemisia princeps* and *A. argyi* from other *Artemisia* herbs. *Biol Pharm Bull* 2006;29:629-33.
 9. Hong JH, Lee IS. Cytoprotective effect of *Artemisia capillaris* fractions on oxidative stress-induced apoptosis in V79 cells. *Biofactors* 2009;35:380-8.
 10. Kwon OS, Choi JS, Islam MN, Kim YS, Kim HP. Inhibition of 5-lipoxygenase and skin inflammation by the aerial parts of *Artemisia capillaris* and its constituents. *Arch Pharm Res* 2011;34:1561-9.
 11. Okuno I, Uchida K, Nakamura M, Sakurawi K. Studies on choleric constituents in *Artemisia capillaris* THUNB. *Chem Pharm Bull (Tokyo)* 1988;36:769-75.
 12. Cho DY, Ko HM, Kim J, Kim BW, Yun YS, Park JI, et al. Scoparone inhibits LPS-simulated inflammatory response by suppressing IRF3 and ERK in BV-2 microglial cells. *Molecules* 2016;21.
 13. Yamahara J, Kobayashi G, Matsuda H, Katayama T, Fujimura H. The effect of scoparone, a coumarin derivative isolated from the Chinese crude drug *Artemisiae capillaris flos*, on the heart. *Chem Pharm Bull (Tokyo)* 1989;37:1297-9.
 14. Zhao C, Chae HJ, Kim SH, Cui WS, Lee SW, Jeon JH, et al. A new perfusion model for studying erectile function. *J Sex Med* 2010;7:1419-28.
 15. Cui X, Lee SJ, Kim SZ, Kim SH, Cho KW. Effects of pituitary adenylate cyclase activating polypeptide27 on cyclic AMP efflux and atrial dynamics in perfused beating atria. *Eur J Pharmacol* 2000;402:129-37.
 16. Chuang AT, Strauss JD, Murphy RA, Steers WD. Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. *J Urol* 1998; 160:257-61.
 17. Schmidt BM, Ribnicky DM, Lipsky PE, Raskin I. Revisiting the ancient concept of botanical therapeutics. *Nat Chem Biol* 2007;3:360-6.
 18. Choi E, Park H, Lee J, Kim G. Anticancer, antiobesity, and anti-inflammatory activity of *Artemisia* species in vitro. *J Tradit Chin Med* 2013;33:92-7.
 19. Hong SH, Seo SH, Lee JH, Choi BT. The aqueous extract from *Artemisia capillaris* Thunb. inhibits lipopolysaccharide-induced inflammatory response through preventing NF-kappaB activation in human hepatoma cell line and rat liver. *Int J Mol Med* 2004;13:717-20.
 20. Cha JD, Jeong MR, Jeong SI, Moon SE, Kim JY, Kil BS, et al. Chemical composition and antimicrobial activity of the essential oils of *Artemisia scoparia* and *A. capillaris*. *Planta Med* 2005;71:186-90.
 21. Choi SR, Ju IO, You DH, Song YE, Jang I, Ryu J. Changes of major components and growth characteristics according to harvesting times of *Artemisia capillaris thunberg*. *Korean J Medicinal Crop Sci* 2007;15:189-93.
 22. Komiya T, Tsukui M, Oshio H. Studies on "Inchinko". I. *Capillarisin*, a new choleric substance (author's transl). *Yakugaku Zasshi* 1976;96:841-54.
 23. Yang CC, Lee MR, Hsu SL, Chang CMJ. Supercritical fluids extraction of capillarisin from *Artemisia capillaris* and its inhibition of in vitro growth of hepatoma cells. *J Supercrit Fluids* 2007;42:96-103.
 24. Huang HC, Lee CR, Weng YI, Lee MC, Lee YT. Vasodilator effect of scoparone (6,7-dimethoxycoumarin) from a Chinese herb. *Eur J Pharmacol* 1992;218:123-8.
 25. Kloner R. Erectile dysfunction and hypertension. *Int J Impot Res* 2007;19:296-302.
 26. Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. *J Diabetes Complications* 2011;25:129-36.
 27. Salonia A, Rigatti P, Montorsi F. Sildenafil in erectile dysfunction: a critical review. *Curr Med Res Opin* 2003;19: 241-62.
 28. Shin YS, Zhao C, Zhang LT, Park JK. Current status and clinical studies of oriental herbs in sexual medicine in Korea. *World J Mens Health* 2015;33:62-72.
 29. Yamashita N, Yamauchi M, Baba J, Sawa A. Phosphodiesterase type 4 that regulates cAMP level in cortical neurons shows high sensitivity to rolipram. *Eur J Pharmacol* 1997; 337:95-102.
 30. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. *Physiol Rev* 1995;75:725-48.